- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01351337
Functional Monitoring for Motor Pathway in Brain Tumor Surgery Within Eloquent Area
April 4, 2015 updated by: Jinsong Wu, Huashan Hospital
Clinical Efficiency of Motor Pathway Mapping Using Diffusion Tensor Imaging Tractography and Intraoperative Subcortical Stimulation in Cerebral Glioma Surgery
Resection of brain tumors in eloquent areas involves the risk of postoperative motor deficits.
For brain tumors within or adjacent to the eloquent area, maximizing tumor resection while preserving motor function is crucially important.we
used DTI-based tractography to visualize the spatial relationship between brain lesions and the nearby pyramidal tract(PT) in patients with malignant brain tumors and confirmed functional connections of the illustrated PT by direct electrical stimulation.
We evaluated the reliability of DTI-based tractography for PT mapping using intraoperative subcortical stimulation ) and the usefulness of the combination of two techniques.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Adverse effects caused by electrical stimulation during the operation were recorded.
All subjects adopted early postoperative MRI examinations (within 3 days) to evaluate both the extent of tumor resection and the integrity of the PTs.
Muscle strength was assessed preoperatively and postoperatively.The Karnofsky Performance Scale (KPS) was adopted for grading functional status at the 6-month evaluation.
Further tumor progression interval and survival analysis was conducted for each subject with high-grade glioma (HGG)
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200000
- Hushan Hospital, Fudan University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 75 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients with an initial imaging diagnosis of single, unilateral, supratentorial primary glioma (or intrinsic neoplasm).
- The lesions were involved in PTs, comprising cortical regions in the motor or somatosensory areas, cortical regions adjacent to the central gyrus, subcortical regions with an infiltrative progression along the PTs, and temporal or insular regions in relation to the internal capsule.
- MRI enabled preoperative identification of patients in whom maximal tumor resection was likely to be achieved, and close PT approach within resection cavity at the time of surgery was possible.
Exclusion Criteria:
- patients with secondary or recurrent gliomas (or intrinsic neoplasm), patients with contraindications for MRI or direct electrical stimulation, and patients in whom initial muscle strength grades of the affected extremities was 2/5 or lower.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: intraoperative functional monitoring
|
All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Extent of Tumor Resection
Time Frame: within 3 days
|
Volumetric analysis was performed both before and after surgery by calculating the tumor volume on the images of enhanced 3-D MP-RAGE sequence for high-grade gliomas and FLAIR sequence for low-grade gliomas.
The extent of tumor resection was the ratio of pre-op tumor volume over post-op tumor volume.
Gross total resection refers to a 100% resection of the tumor volume; near-total resection refers to 95% to 100% resection; subtotal resection refers to 90% to 95% resection; partial resection refers to 75% to 90% resection; and biopsy refers to ,75% resection of the tumor volume for histological diagnosis.
|
within 3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative Motor Function and Long-time Functional Status
Time Frame: 3 days to 6 months after surgery
|
Motor function was assessed early postoperatively (within 72 hours after the operation), and 1 month after discharge.
The muscle strength of each subject was graded for both the upper and lower extremities with the Medical Research Council Scale.
Grade 5: Muscle contracts against full resistance; Grade 4: Strength reduced, but contraction can still move joint against resistance; Grade 3: Strength further reduced such that joint can be moved only against gravity with examiner's resistance completely removed.
Grade 2: Muscle can onlly move if resistance of gravity is removed.
Grade 1: Only a trace or flicker of movement is seen or felt, or fasciculations are observed; Grade 0:No movement.
|
3 days to 6 months after surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Specificity, Sentitivity of DTI Tractography and Accordance Rate of DTI With DsCS Results
Time Frame: During the operation
|
The sensitivity of DTI tractography for PT mapping was calculated as the ratio between the number of subjects with positive DsCS results in the positive DTI zone (true positive) and the total number of subjects with positive DsCS results (true positive plus false negative).
The specificity was measured as the ratio between the number of subjects with negative DsCS results in the negative DTI zone (true negative) and the total number of subjects with negative DsCS results (true negative plus false positive).
The accordance rate of DsCS and DTI was measured as the ratio between the number of subjects with either a true-positive or true-negative DsCS result and the total number of subjects.
|
During the operation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Liangfu Zhou, Doctorate, Huashan Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2008
Primary Completion (Actual)
June 1, 2009
Study Completion (Actual)
February 1, 2013
Study Registration Dates
First Submitted
May 9, 2011
First Submitted That Met QC Criteria
May 9, 2011
First Posted (Estimate)
May 10, 2011
Study Record Updates
Last Update Posted (Estimate)
April 20, 2015
Last Update Submitted That Met QC Criteria
April 4, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07QA14008 (Other Grant/Funding Number: The govermment of Shanghai, China)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioma, Motor Pathway
-
National Institute of Mental Health (NIMH)Recruiting
-
National Cancer Institute (NCI)Active, not recruitingLow Grade Glioma | Recurrent Visual Pathway Glioma | Refractory Visual Pathway Glioma | Recurrent Childhood Pilocytic Astrocytoma | Recurrent Neurofibromatosis Type 1 | Refractory Neurofibromatosis Type 1United States
-
St. Jude Children's Research HospitalRecruitingGlioma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Pilocytic Astrocytoma | Optic Pathway Glioma | Pilomyxoid AstrocytomaUnited States
-
Erik MittraNational Cancer Institute (NCI)TerminatedUntreated Childhood Brain Stem Glioma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pilocytic Astrocytoma | Adult Pineal Gland Astrocytoma and other conditionsUnited States
-
Northwestern UniversityWithdrawn
-
University of East AngliaCompletedImplementation of Enhanced Recovery Pathway
-
Nested Therapeutics, IncRecruitingGlioma | Melanoma | NSCLC | Oncology | Solid Tumor, Adult | MEK Mutation | RAF Gene Mutation | Ras (KRAS or NRAS) Gene Mutation | MAPK Pathway Gene MutationAustralia
-
Beijing Sanbo Brain HospitalRecruitingOptic Glioma | Pediatric Brain Tumor, Optic Nerve GliomaChina
Clinical Trials on diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation
-
Fundació Institut de Recerca de l'Hospital de la...UnknownIntracranial Neoplasm
-
Huashan HospitalShanghai Zhongshan Hospital; Huashan Hospital North, Fudan UniversityNot yet recruiting